Although the mutated form is a neoantigen almost exclusively found in AML [14], and generally expressed in the entire leukemic population, while not detectable in clonal hematopoiesis, there is a theoretical concern that NPMmut CTLs, once administered to patients, could recognize wt-NPM1 on non-leukemic hematopoietic progenitors and mediate BM toxicity. Here, NPM1 is linked to acute myeloid leukemia.